BDBM230103 US10106559, Example 27::US10435415, Example 27::US9334290, 27::US9850258, Example 27

SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@@H](CCc3c12)C(C)(C)O

InChI Key InChIKey=ZRYMMWAJAFUANM-UHFFFAOYSA-N

Data  13 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 13 hits for monomerid = 230103   

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 2.20nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 2.20nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 2.20nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 2.20nMAssay Description:Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2018
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 2.20nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2017
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 36nMAssay Description:Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2018
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 88nMAssay Description:Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr fol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 150nMAssay Description:Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2018
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 374nMAssay Description:Inhibition of BTK in human whole blood derived-basophils assessed as suppression of IgE mediated-FcepsilonR ligation-stimulated CD63 expressionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 2.00E+3nMpH: 7.4 T: 2°CAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2017
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 2.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 2.00E+3nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230103(US9334290, 27 | US10106559, Example 27 | US9850258...)
Affinity DataIC50: 2.00E+3nMAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
US Patent